ID   T24R2
AC   CVCL_E9WA
RX   CelloPub=CLPUB00806;
CC   Population: Caucasian; Swedish.
CC   Doubling time: 28.2 +- 2.8 hours (CelloPub=CLPUB00806).
CC   Selected for resistance to: ChEBI; CHEBI_27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; HGNC:5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 14-08-25; Last updated: 14-08-25; Version: 1
//
RX   CelloPub=CLPUB00806;
RA   Lee, Eunsik
RA   Kwak, Cheol
RA   Byun, Seok-Soo
RA   Lim, Dae Jung
RA   Kim, Jeong Hyun
RA   Kim, Soo Woong
RA   Lee, Chongwook
RA   Ahn, Han-Jong
RT   "Establishment and characterization of cisplatin-resistant human
RT   bladder cancer cells.";
RL   Korean J. Urol. Oncol. 1:186-192(2003).
//